Bank S, Singh P, Pooran N, et al. Evaluation of factors that have reduced mortality from acute pancreatitis over the past 20 years[J]. J Clin Gastroenterol, 2002, 35(1): 50-60.
[2]
Gross V, Andreesen R, Leser HG, et al. Interleukin-8 and neutrophil activation in acute pancreatitis[J]. Eur J Clin Invest, 1992, 22(3): 200-203.
[3]
Carroll JK, Herrick B, Gipson T, et al. Acute pancreatitis: diagnosis, prognosis, and treatment[J]. Am Fan physician, 2007, 75(10): 1513-1520.
Hartwig W, Maksan SM, Foitzik T, et al. Reduction in mortality with delayed surgical theraphy of severe pancreatitis[J]. J Gastrointest Surg, 2002, 6(3): 481-487.
Zhang Q, Ni Q, Cai D, et al. Mechanisms of multiple organ damages in acute necrotizing pancreatitis[J]. Chin Med J, 2001, 114(7): 738-742.
[13]
Oruc N, Ozutemiz AO, Yukselen V, et al. Infliximab: a new therapeutic agent in acute pancreatitis[J]. Pancreas, 2004, 28(1): 1-8.
[14]
Bhatia M, Brady M, Shokuhi S, et al. Inflammatory mediators in acute pancreatitis[J]. J Pathol, 2000, 190(2): 117-125.
[15]
Steinberg W, Tenner S. Acute pancreatitis[J]. N Engl J Med, 1994, 330(17): 1198-1220.
[16]
Inagaki T, Hoshino M, Hayakawa T, et al. Interleukin-6 is a useful marker for early prediction of the severity of acute pancreatitis[J]. Pancreas, 1997(1), 14: 1-8.
Dugernier TL, Laterre PF, Wint tebole X, et al. Compartmentalization of the inflammatory response during acute pancreatitis: correlation with local and systemic complications[J]. Am J Respir Crit Care Med, 2003, 168(2): 148-157.
